Lannett Company, Inc.
https://www.lannett.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Lannett Company, Inc.
Cipla's Advair Generic Debut In Sight, More Platform Deals On Radar Post Ethris
Cipla believes it is “pretty close” to approval for its Advair generic in the US, while another product, generic Abraxane, stands delayed currently. Following the deal with Ethris, which is progressing inhaled mRNA-based therapies, the company signals interest in platforms such as CAR-T as well.
US Q3 Health And Wellness Results: Chromadex, Lannett, Mannatech And USANA
ChromaDex trims loss, adds Nestle as Niagen customer; currency exchange slams Mannatech; Asia-Pacific sales, currency exchange Rock USANA results; and Lannett sees upsides after 25% sales slide.
Cipla Stays Upbeat On Advair Generic With ‘Superior’ Cost Position, Derisks Abraxane
Generic Revlimid and lanreotide propel Cipla’s US business to a high in the fiscal second quarter, with products like leuprolide depot set for debut ‘any time now’. Management signals cost edge for generic Advair as it awaits further word following a FDA establishment inspection report at its Indian site, while a Plan B is being initiated for generic Abraxane.
Lannett Eyes Insulins Opportunity And Advances Respiratory Assets
Lannett has offered the latest updates on its pipeline of respiratory complex generics and insulin biosimilars – including the potential for the firm to receive the first US biosimilar aspart approval.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
- Other Names / Subsidiaries
-
- Kremers Urban Pharmaceuticals, Cody Laboratories, Silarx Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice